Literature DB >> 6705579

Amikacin concentrations in uninfected postthoracotomy pleural fluid and in serum after intravenous and intrapleural injection.

J P Thys, E Serruys-Schoutens, P Rocmans, A Herchuelz, M P Vanderlinden, E Yourassowsky.   

Abstract

The pharmacokinetics of amikacin after intravenous (IV) and intrapleural injection was compared in 25 patients with pleural drainage after lung resection. In ten patients 7.5 mg/kg of the drug was injected IV; the mean peak concentrations were 31.2 +/- 2.3 micrograms/ml in the serum and 13.3 +/- 3.8 micrograms/ml in the pleural fluid. The penetration of amikacin in the pleural space was 80 percent. After the intrapleural injection of the same dose of amikacin in 15 patients, the pleural fluid concentrations of the drug were extremely high and well sustained during eight hours; however, serum concentrations reached maximal values of 14.1 +/- 4.7 micrograms/ml, indicating a substantial diffusion of amikacin from the pleural space to the blood. In the case of treatment of pleural infections by local injection of aminoglycosides, the serum concentrations must be kept in mind to avoid systemic intoxication from these drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705579     DOI: 10.1378/chest.85.4.502

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff.

Authors:  Patrica M L A van den Bemt; Maarten J Postma; Eric N van Roon; Man-Chie C Chow; Roel Fijn; Jacobus R B J Brouwers
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Amikacin concentrations in serum following intraoperative irrigation of the pleura and peritoneum.

Authors:  C W Van Way; G Hasse
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

3.  Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.

Authors:  Tan N Doan; Pengxing Cao; Theophilus I Emeto; James M McCaw; Emma S McBryde
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

4.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

5.  Sustained release of bactericidal concentrations of penicillin in the pleural space via an antibiotic-eluting pigtail catheter coated with electrospun nanofibers: results from in vivo and in vitro studies.

Authors:  Yin-Kai Chao; Cheng-Hung Lee; Kuo-Sheng Liu; Yi-Chuan Wang; Chih-Wei Wang; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2015-05-04

Review 6.  Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Authors:  Tetsuya Matsumoto
Journal:  Clin Pharmacol       Date:  2014-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.